Camptosar

(Irinotecan)

ApprovedSmall molecule

Irinotecan is a chemotherapy drug used to treat certain types of cancer, including colorectal cancer and small cell lung cancer, by damaging cancer cell DNA to stop them from growing.[2] Camptosar is currently approved and in use across 84 indications[4].[1]

Camptosar is one of 1225 small molecule programs targeting Glioma. It is currently in Approved.

Indications

634

Total Trials

Active Trials

1,224

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Pancreatic CarcinomaActive, not recruiting

Pancreatic NeoplasmApproved

Peritoneum CancerApproved

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Colorectal CarcinomaActive, not recruiting

MetastasisApproved

Esophageal Squamous Cell CarcinomaActive, not recruiting

Esophageal CarcinomaActive, not recruiting

ParagangliomaApproved

GliomaPhase 1

Active, not recruiting

Pancreatic CarcinomaPhase 3

Active, not recruiting

Pancreatic NeoplasmApproved

Approved

Peritoneum CancerApproved

Approved

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Colorectal CarcinomaPhase 2

Active, not recruiting

MetastasisApproved

Approved

Esophageal Squamous Cell CarcinomaPhase 3

Active, not recruiting

Esophageal CarcinomaPhase 2

Active, not recruiting

ParagangliomaApproved

Approved

Showing 10 of 84 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Approved

3 2

Tykerb

GSK

Preclinical

80 3

MS Contin

Merck & Co.

Preclinical

2 4

Zolymbus

AbbVie

Preclinical

1 5

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 6

Spravato

WWim Janssens

Preclinical

2 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Vfend

PPrism Pharmaceuticals

Preclinical

—9

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 10

Bisphosphonate

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Active, not recruiting

Colorectal Cancer

NCT05846867

Phase 2Active, not recruiting

Efficacy and Safety

NCT05312398

Q4 2026

Phase 2Active, not recruiting

Gastroesophageal Junction Adenocarcinoma

NCT03773367

Phase 3Active, not recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06351020

Phase 2Recruiting

Unresectable

NCT05727163

Phase 1Recruiting

Colon Adenocarcinoma

NCT04920032

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer25 trials

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Active, not recruiting·AAkeso·Phase 2·NCT05382442·254 enrolled

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Terminated· Pfizer logo

Pfizer·Phase 2·NCT01925274·19 enrolled

Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer

Withdrawn·FFujian Cancer Hospital·Phase 1·NCT03380689

Show 22 more trials

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT04607421·831 enrolled

Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

Terminated· Gilead logo

Gilead·Phase 2·NCT05330429·77 enrolled

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Completed·—·Phase 2·NCT02292758·36 enrolled

EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT01008475·232 enrolled

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

Unknown status·SShanghai JMT-Bio Inc.·Phase 2·NCT06089330·102 enrolled

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Active, not recruiting·—·Phase 2·NCT04117945·22 enrolled

Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT02138617·100 enrolled

A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer

Unknown status· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT02453464·36 enrolled

FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients

Unknown status·FFudan University·Phase 3·NCT02935764·164 enrolled

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT02928224·702 enrolled

Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer

Terminated· Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.·Phase 1/2·NCT00838578·65 enrolled

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1/2·NCT01075048·131 enrolled

Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 2·NCT00022698·67 enrolled

A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 2·NCT00048126·57 enrolled

The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT07134205·252 enrolled

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

Not yet recruiting·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT07150403·74 enrolled

AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients

Completed·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT04513951·62 enrolled

Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.

Unknown status·HHôpital Franco-Britannique-Fondation Cognacq-Jay·Phase 2·NCT04189055·72 enrolled

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.

Withdrawn· Roche logo

Roche·Phase 2·NCT00577109

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT01896856·118 enrolled

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

Completed·—·Phase 2·NCT00730158·33 enrolled

Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT00126256·570 enrolled

Colorectal Cancer19 trials

Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis

Withdrawn·WWake Forest University Health Sciences·N/A·NCT01847495

Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia

Unknown status·FFudan University·Phase 2·NCT03823079·50 enrolled

Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT00766220

Show 16 more trials

FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer

Unknown status·SSun Yat-sen University·Phase 3·NCT01566942·200 enrolled

Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02414009·82 enrolled

High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28

Unknown status·SShanghai Changzheng Hospital·Phase 2·NCT03329183·90 enrolled

Colorectal Cancer Metastatic

Completed· Sanofi logo

Sanofi·Phase 3·NCT01670721·175 enrolled

Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer

Withdrawn·WWeill Medical College of Cornell University·Phase 2·NCT02046538

Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy

Completed·UUniversity of Pittsburgh·Phase 2·NCT00336856·35 enrolled

Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients

Completed·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT04072198·73 enrolled

Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

Unknown status·JJiangsu Cancer Institute & Hospital·Phase 2·NCT03126071·100 enrolled

5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

Unknown status·PPD Dr. med. Volker Heinemann·Phase 3·NCT00433927·568 enrolled

A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer

Active, not recruiting·AAkeso·Phase 1/2·NCT05846867·170 enrolled

Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients

Unknown status·—·Phase 2·NCT03053167·100 enrolled

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Completed·NNektar Therapeutics·Phase 2·NCT00856375·83 enrolled

Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00215982·24 enrolled

Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer

Terminated·HHellenic Oncology Research Group·Phase 2·NCT00681876·16 enrolled

Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants

Completed·IInstitut de Recherche Clinique sur les Cancers et le Sang·Phase 4·NCT00138060·71 enrolled

FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer

Unknown status·WWest China Hospital·Phase 2·NCT05018182·69 enrolled

Pancreatic Cancer13 trials

The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer

Unknown status·FFudan University·Phase 2·NCT03403101·65 enrolled

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

Active, not recruiting·SSeoul National University Hospital·Phase 2·NCT04447092·77 enrolled

Nordic Pancreatic Cancer Trial (NorPACT) - 1

Active, not recruiting·OOslo University Hospital·Phase 2/3·NCT02919787·140 enrolled

Show 10 more trials

Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT01296763·18 enrolled

A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Terminated·—·Phase 2·NCT05546411·8 enrolled

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Recruiting·MMayo Clinic·Phase 2·NCT06381154·25 enrolled

Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer

Terminated·UUniversity of Pittsburgh·Phase 1·NCT00177853·23 enrolled

Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer

Completed·SStanford University·Phase 3·NCT01926197·27 enrolled

Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT06166589·19 enrolled

Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen

Unknown status·FFudan University·Phase 2·NCT04101929·126 enrolled

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Completed· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 1·NCT06538207·46 enrolled

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT01821612·23 enrolled

Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer

Unknown status·LLudwig-Maximilians - University of Munich·Phase 2·NCT01729481·150 enrolled

Small Cell Lung Cancer12 trials

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00695292·37 enrolled

Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)

Terminated·WWashington University School of Medicine·Phase 1·NCT05049863·17 enrolled

Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00308529·55 enrolled

Show 9 more trials

SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Unknown status·BBiocity Biopharmaceutics Co., Ltd.·Phase 1/2·NCT05731518·67 enrolled

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

Completed· United Therapeutics logo

United Therapeutics·Phase 2/3·NCT03098030·483 enrolled

A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT06954246·450 enrolled

Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer

Unknown status·TThird Military Medical University·Phase 2·NCT01977235·110 enrolled

A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Unknown status·NNational Cancer Center, Korea·Phase 1/2·NCT00874328·74 enrolled

Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193375·60 enrolled

Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193349·60 enrolled

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Completed·CCancer Research and Biostatistics Clinical Trials Consortium·Phase 1/2·NCT01941316·78 enrolled

Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)

Completed·NNational Cancer Center, Korea·Phase 2·NCT00452634·62 enrolled

Chemotherapy6 trials

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

Completed·—·Phase 1·NCT02021422·13 enrolled

Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT01677884·10 enrolled

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

Terminated·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT05039944·7 enrolled

Show 3 more trials

Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM

Terminated·SSun Yat-sen University·Phase 3·NCT03500874·92 enrolled

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Recruiting· Astellas logo

Astellas·Phase 1·NCT07024615·25 enrolled

Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

Not yet recruiting·JJohn Neoptolemos·Phase 3·NCT05314998·394 enrolled

77 more indications

Gastric Cancer6 trials

ILF With/Without Cisplatin for Advanced Gastric Cancer

Unknown status·GGachon University Gil Medical Center·Phase 2·NCT00320294·86 enrolled

Irinotecan as 3rd Line Therapy in Gastric Cancer

Unknown status·FFudan University·Phase 2·NCT02662959·93 enrolled

Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer

Completed·JJapan Clinical Cancer Research Organization·Phase 2/3·NCT00639327·300 enrolled

Show 3 more trials

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 3·NCT02625623·371 enrolled

Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer

Completed·—·Phase 2·NCT00165464·54 enrolled

Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT05669807·184 enrolled

Esophageal Squamous Cell Carcinoma6 trials

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Active, not recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 3·NCT06304974·497 enrolled

Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma

Completed·PPeking University·Phase 1·NCT02645864·12 enrolled

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Completed·FFudan University·Phase 2·NCT03797625·52 enrolled

Show 3 more trials

Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT03387904·120 enrolled

Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)

Completed· Novartis logo

Novartis·Phase 1·NCT01822613·48 enrolled

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

Terminated· BeiGene logo

BeiGene·Phase 2·NCT05461794·96 enrolled

Advanced Cancer5 trials

OSI-906 and Irinotecan in Patients With Advanced Cancer

Terminated·UUniversity of Colorado, Denver·Phase 1·NCT01016860·16 enrolled

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

Terminated· Pfizer logo

Pfizer·Phase 1·NCT01347866·105 enrolled

Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)

Terminated·WWestern Regional Medical Center·Phase 1/2·NCT02423954·33 enrolled

Show 2 more trials

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Terminated·WWestern Regional Medical Center·Phase 1/2·NCT02331251·81 enrolled

RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)

Terminated·EEpicentRx, Inc.·Phase 1·NCT02801097·28 enrolled

Esophageal Cancer4 trials

Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer

Completed·—·Phase 2·NCT00165490·19 enrolled

Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial

Completed·UUniversity Hospital, Rouen·Phase 2·NCT00213486·43 enrolled

Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT01928290·67 enrolled

Show 1 more trial

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03099382·457 enrolled

Patients With Solid Tumors3 trials

Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors

Completed·DDorte Nielsen·Phase 1·NCT03295084·39 enrolled

Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors

Completed·HHMeany·Phase 1·NCT01518413·17 enrolled

Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors

Unknown status·BBiotech Pharmaceutical Co., Ltd.·Phase 1·NCT02395068·40 enrolled

Clinical Trial3 trials

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

Recruiting·—·N/A·NCT05391126·178 enrolled

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT05999994·105 enrolled

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Completed· Sanofi logo

Sanofi·Phase 3·NCT01593228·37 enrolled

Adenocarcinoma3 trials

JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT07284134·560 enrolled

Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01560949·34 enrolled

FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)

Unknown status·—·Phase 2·NCT04442984·326 enrolled

Refractory Solid Tumors3 trials

A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00057473

A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00990912·20 enrolled

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Active, not recruiting· Pfizer logo

Pfizer·Phase 2·NCT03709680·128 enrolled

Fluorouracil3 trials

Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination

Completed· Sanofi logo

Sanofi·Phase 1·NCT00507091·24 enrolled

A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01286818·6 enrolled

Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01046864·49 enrolled

Temozolomide3 trials

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Recruiting·NNationwide Children's Hospital·Phase 1/2·NCT04211675·31 enrolled

Study of MLN8237 in Combination With Irinotecan and Temozolomide

Completed·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1/2·NCT01601535·54 enrolled

Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy

Completed·UUniversity of Oklahoma·Phase 1·NCT00222443·40 enrolled

Glioblastoma Multiforme3 trials

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

Unknown status·LLeaf Vertical Inc.·Phase 1/2·NCT03607643·160 enrolled

Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme

Completed·KKaty Peters·Phase 2·NCT00979017·41 enrolled

Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT00671801·24 enrolled

Colorectal Carcinoma2 trials

CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin

Terminated· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT00969033·8 enrolled

Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma

Completed·HHiberCell, Inc.·Phase 1/2·NCT00545545·32 enrolled

Advanced Solid Tumors2 trials

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03184870·332 enrolled

Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors

Completed· Sanofi logo

Sanofi·Phase 1·NCT00298675·59 enrolled

Malignant Glioma2 trials

Panitumumab and Irinotecan for Malignant Gliomas

Terminated·AAnnick Desjardins·Phase 2·NCT01017653·16 enrolled

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

Completed·—·Phase 2·NCT00352521·20 enrolled

Biliary Tract Cancer2 trials

Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer

Completed·MMayo Clinic·Phase 2·NCT04072445·28 enrolled

GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer

Unknown status·—·Phase 2·NCT01859728·48 enrolled

Esophageal Adenocarcinoma2 trials

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

Completed·UUniversity of California, Irvine·Phase 1·NCT04074343·20 enrolled

Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas

Terminated·UUNICANCER·Phase 1/2·NCT03722108·89 enrolled

Medulloblastoma2 trials

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

Not yet recruiting·SSabine Mueller, MD, PhD·Phase 1/2·NCT07346157·69 enrolled

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Recruiting·MMedical University of Vienna·Phase 2·NCT01356290·232 enrolled

Patients With Advanced Solid Tumors2 trials

A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

Terminated· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 2·NCT05148195·86 enrolled

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Terminated· Roche logo

Roche·Phase 1·NCT00811993·104 enrolled

Efficacy and Safety2 trials

Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen

Completed·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT03279289·170 enrolled

CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

Active, not recruiting·UUniversity of Campania Luigi Vanvitelli·Phase 2·NCT05312398·219 enrolled

Gastroesophageal Junction Adenocarcinoma2 trials

Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.

Active, not recruiting·LLund University Hospital·Phase 2·NCT03773367·60 enrolled

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Active, not recruiting·LLaNova Medicines Zhejiang Co., Ltd.·Phase 3·NCT06351020·387 enrolled

Treatment2 trials

FOLFIRINOX for 2nd-line Treatment of BTC

Completed·—·Phase 2·NCT03778593·34 enrolled

SMMART Adaptive Clinical Treatment (ACT) Trial

Withdrawn·OOHSU Knight Cancer Institute·Phase 1·NCT05238831

Ewing sarcoma2 trials

Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT05042934

Anlotinib and Irinotecan for Ewing Sarcoma

Unknown status·PPeking University People's Hospital·Phase 1/2·NCT03416517·47 enrolled

Ewing's Sarcoma2 trials

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

Terminated·GGradalis, Inc.·Phase 3·NCT03495921·32 enrolled

Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

Terminated·SStanford University·Phase 2·NCT01313884·3 enrolled

Tics2 trials

Effect of Panitumumab on the Pharmacokinetics of Irinotecan

Completed· Amgen logo

Amgen·Phase 1·NCT00563316·28 enrolled

A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01634555·29 enrolled

Pancreatic Adenocarcinoma2 trials

A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma

Completed·EEndeavor Health·Phase 2·NCT01660711·22 enrolled

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Completed·OOncolytics Biotech·Phase 1·NCT02620423·11 enrolled

PD-1antibody2 trials

PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC

Unknown status·SSun Yat-sen University·Phase 3·NCT05737563·380 enrolled

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Active, not recruiting· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 2·NCT05945823·53 enrolled

Locally-advanced Rectal Cancer2 trials

Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00081289·146 enrolled

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

Recruiting·UUniversity of Miami·Phase 1·NCT05412082·25 enrolled

Gastroesophageal Junction Cancer2 trials

Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

Terminated·KKuhnil Pharmaceutical Co., Ltd.·Phase 3·NCT01813253·400 enrolled

FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer

Terminated·AAlliance for Clinical Trials in Oncology·Phase 2·NCT02485834·5 enrolled

Neuroblastoma1 trial

Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children

Active, not recruiting·UUniversity of Birmingham·Phase 2·NCT02308527·225 enrolled

Fibrolamellar Carcinoma1 trial

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Recruiting·CChildren's Oncology Group·Phase 1/2·NCT06620302·81 enrolled

Desmoplastic Small Round Cell Tumor1 trial

A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT04095221·21 enrolled

Recurrent or Metastatic1 trial

Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma

Terminated·UUniversity of California, Irvine·Phase 2·NCT00256269·4 enrolled

Lymphoma1 trial

Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors

Active, not recruiting·SSun Yat-sen University·Phase 1·NCT05620862·68 enrolled

Trial1 trial

Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan

Completed·UUniversity of Southern California·Phase 1·NCT00183859·42 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting·UUniversity of Miami·Phase 2·NCT07096362·50 enrolled

Advanced Solid Malignancies1 trial

A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies

Completed· Sanofi logo

Sanofi·Phase 1·NCT01930552·20 enrolled

Resistance1 trial

Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

Completed·NNantBioScience, Inc.·Phase 2·NCT00891930·74 enrolled

Rhabdomyosarcoma1 trial

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Recruiting·UUniversity of Birmingham·Phase 1/2·NCT04625907·1,672 enrolled

Hepatocellular Carcinoma1 trial

AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma

Recruiting·UUniversity of Florida·Phase 2·NCT05669339·12 enrolled

Pediatric Patients1 trial

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Terminated·AActuate Therapeutics Inc.·Phase 1·NCT04239092·40 enrolled

Gastric Adenocarcinoma1 trial

Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma

Unknown status·PPeking University·Phase 2·NCT03400592·55 enrolled

Metastases1 trial

Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases

Completed·UUNICANCER·Phase 2·NCT01442935·256 enrolled

NSCLC Stage III1 trial

Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV

Completed·HHellenic Oncology Research Group·Phase 2·NCT00614965·124 enrolled

Unresectable1 trial

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

Recruiting·SSun Yat-sen University·Phase 2·NCT05727163·194 enrolled

Esophageal Carcinoma1 trial

Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00590031·61 enrolled

Cancers1 trial

Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair

Completed·PPamela Munster·Phase 1·NCT03318445·22 enrolled

Glioma1 trial

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

Completed·JJulie Krystal·Phase 1/2·NCT01837862·36 enrolled

CNS Tumors1 trial

A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors

Completed·UUniversity of New Mexico·Phase 1·NCT00251797·10 enrolled

Chemoradiotherapy1 trial

Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer

Unknown status·FFudan University·Phase 1·NCT01474187·60 enrolled

Solid Tumor Cancer1 trial

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT05004116·77 enrolled

Transplantation1 trial

Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos

Unknown status·UUniversity of Pisa··NCT03668418·120 enrolled

Intraperitoneal1 trial

Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab

Unknown status·CCatharina Ziekenhuis Eindhoven·Phase 2·NCT06003998·85 enrolled

Pembrolizumab1 trial

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Recruiting· Astellas logo

Astellas·Phase 1/2·NCT05083481·366 enrolled

Unresectable Colorectal Liver Metastases1 trial

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Recruiting·EECOG-ACRIN Cancer Research Group·Phase 3·NCT05863195·408 enrolled

Gastric1 trial

Phase I Study of Interperitoneal Chenotherapy in Patients With Gastric Adenocarainoma With Peritoneal Seeding

Completed·SSamsung Medical Center·Phase 1·NCT00539877·17 enrolled

Phase II1 trial

Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005626·10 enrolled

Bevacizumab1 trial

Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc

Terminated·—·Phase 2·NCT00755118·24 enrolled

Relapse1 trial

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

Recruiting· Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.·Phase 3·NCT06496048·180 enrolled

Peritoneal Carcinomatosis1 trial

Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin

Completed·EErasmus Medical Center·Phase 1·NCT05379790·20 enrolled

Carcinoma of Unknown Primary1 trial

Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

Completed·SSCRI Development Innovations, LLC·Phase 3·NCT00193596·198 enrolled

Colon Adenocarcinoma1 trial

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Recruiting·UUniversity of California, Irvine·Phase 1·NCT04920032·22 enrolled

Locally Advanced Colon Cancer1 trial

Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer

Unknown status·—·Phase 2·NCT01826396·100 enrolled

Diffuse Intrinsic Pontine Glioma1 trial

A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas

Completed·—·Phase 1·NCT00890786·27 enrolled

Cancer1 trial

Phase I/II Trial of Antagonism of HER in GI Cancer

Completed·UUniversity College, London·Phase 2·NCT01862003·24 enrolled

Microsatellite Instability1 trial

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Active, not recruiting· Novartis logo

Novartis·Phase 1·NCT05838768·123 enrolled

Tislelizumab1 trial

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Recruiting·FFujian Cancer Hospital·Phase 1/2·NCT05319639·51 enrolled

Solid Tumor Malignancies1 trial

Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies

Completed·—·Phase 1·NCT00215501·54 enrolled

Liver Cancer1 trial

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT03533582·537 enrolled

Randomized1 trial

Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC

Completed·HHellenic Oncology Research Group·Phase 3·NCT00469443·330 enrolled

Single Ascending Dose1 trial

Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT00473616·60 enrolled

CRC1 trial

Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT03493048·146 enrolled

Second-line Treatment1 trial

A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients

Unknown status·—··NCT06169202·50 enrolled

Liquid Biopsy1 trial

Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB

Recruiting·AAzienda USL Reggio Emilia - IRCCS·Phase 3·NCT04776655·280 enrolled

Combination Therapy1 trial

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Recruiting·UUniversity of California, San Francisco·Phase 1·NCT05694715·24 enrolled

Solid Tumors1 trial

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Completed·PPharmaMar·Phase 1/2·NCT02611024·316 enrolled

Breast Cancer1 trial

Irinotecan for Advanced and Metastatic Breast Cancer

Unknown status·LLiaoning Cancer Hospital & Institute·Phase 2·NCT03562390·124 enrolled

Unspecified1 trial

M6620 First in Human Study

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT02157792·200 enrolled

Regulatory

FDA Approval Timeline[5]

Jun 14, 1996

CAMPTOSAR

NDA NDA020571

Oct 22, 2015

ONIVYDE

NDA NDA207793

Sources

References

[1]
ClinicalTrials.gov — 634 trial records for Irinotecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Camptosar drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Irinotecan compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Irinotecan. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA207793). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Camptosar. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Topoisomerase I Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Pfizer

Patent Landscape[6]

Patent Cliff

Jan 6, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8329213Jan 6, 2027

8147867Aug 29, 2028

9364473Jun 12, 2033

12364691Jun 12, 2033

11369597Jun 12, 2033

9 more patents

9339497Jun 12, 2033

9452162Jun 12, 2033

10980795Jun 12, 2033

9717724Jun 12, 2033

9492442Jun 12, 2033

11344552Aug 19, 2036

12059497Oct 15, 2036

10456360Oct 15, 2036

10993914Oct 15, 2036